This article was originally published in The Gray Sheet
Executive SummaryExclusive worldwide license to Focal lung and kidney post-biopsy applications granted by Genzyme to the Biopsy Sciences subsidiary. Genzyme Biosurgery will supply materials and polymer expertise to Bio-Seal, which will manufacture and distribute any products resulting from the agreement...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.